Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 3
1992 1
1993 3
1994 5
1995 6
1996 6
1997 1
1998 3
1999 4
2000 1
2001 7
2002 13
2003 10
2004 28
2005 24
2006 53
2007 34
2008 51
2009 46
2010 63
2011 72
2012 94
2013 89
2014 99
2015 85
2016 95
2017 79
2018 76
2019 73
2020 60
2021 68
2022 57
2023 48
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

1,228 results

Results by year

Filters applied: . Clear all
Page 1
The Role of Ranolazine in Heart Failure-Current Concepts.
Kourampi I, Katsioupa M, Oikonomou E, Tsigkou V, Marinos G, Goliopoulou A, Katsarou O, Kalogeras K, Theofilis P, Tsatsaragkou A, Siasos G, Tousoulis D, Vavuranakis M. Kourampi I, et al. Am J Cardiol. 2023 Dec 15;209:92-103. doi: 10.1016/j.amjcard.2023.09.066. Epub 2023 Oct 13. Am J Cardiol. 2023. PMID: 37844876 Review.
Ranolazine's therapeutic mechanisms in myocardial ion channels and energy utilization are documented in patients with chronic coronary syndromes. Nevertheless, ranolazine might have a broader effect in the therapy of heart failure and further mechanistic rese …
Ranolazine's therapeutic mechanisms in myocardial ion channels and energy utilization are documented in patients with chronic …
Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction.
Sharp RP, Patatanian E, Sirajuddin R. Sharp RP, et al. Am J Cardiovasc Drugs. 2021 Sep;21(5):513-521. doi: 10.1007/s40256-020-00462-6. Epub 2021 Jan 13. Am J Cardiovasc Drugs. 2021. PMID: 33438139 Review.
Data are lacking for ranolazine use as the sole agent for CMD treatment. Some questions remain to be answered regarding ranolazine use for CMD. Larger studies of longer duration are needed to verify the effectiveness of ranolazine in the treatment of CMD....
Data are lacking for ranolazine use as the sole agent for CMD treatment. Some questions remain to be answered regarding ranolazine …
Metabolic and Cognitive Effects of Ranolazine in Type 2 Diabetes Mellitus: Data from an in vivo Model.
Cassano V, Leo A, Tallarico M, Nesci V, Cimellaro A, Fiorentino TV, Citraro R, Hribal ML, De Sarro G, Perticone F, Sesti G, Russo E, Sciacqua A. Cassano V, et al. Nutrients. 2020 Jan 31;12(2):382. doi: 10.3390/nu12020382. Nutrients. 2020. PMID: 32023991 Free PMC article.
Animals were divided into the following groups: HFD/STZ + Ranolazine, HFD/STZ + Metformin, HFD/STZ + Vehicle, NCD + Vehicle, NCD + Ranolazine, and NCD + Metformin. ...Ranolazine improved learning and long-term memory in HFD/STZ + Ranolazine compared to …
Animals were divided into the following groups: HFD/STZ + Ranolazine, HFD/STZ + Metformin, HFD/STZ + Vehicle, NCD + Vehicle, NCD + …
Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis.
Ayyasamy L, Bagepally BS. Ayyasamy L, et al. Clin Ther. 2023 May;45(5):458-465. doi: 10.1016/j.clinthera.2023.04.004. Epub 2023 Apr 21. Clin Ther. 2023. PMID: 37087299 Review.
PURPOSE: Ranolazine is used to treat stable angina pectoris, the most common symptom of ischemic heart disease. ...The current evidence synthesis may provide a macroeconomic point of view for policy makers regarding the direction of ranolazine's cost-effectiv …
PURPOSE: Ranolazine is used to treat stable angina pectoris, the most common symptom of ischemic heart disease. ...The current eviden …
Ranolazine Therapy in Cardiac Arrhythmias.
Pulford BR, Kluger J. Pulford BR, et al. Pacing Clin Electrophysiol. 2016 Sep;39(9):1006-15. doi: 10.1111/pace.12905. Epub 2016 Jul 23. Pacing Clin Electrophysiol. 2016. PMID: 27358212 Review.
Ranolazine is an antianginal medication originally granted approval by the U.S. ...This article will review the basic pharmacology of ranolazine, the studies demonstrating use of ranolazine in atrial and ventricular arrhythmias, the limitations to the use of …
Ranolazine is an antianginal medication originally granted approval by the U.S. ...This article will review the basic pharmacology of …
Role of ranolazine in heart failure: From cellular to clinic perspective.
Kaplan A, Amin G, Abidi E, Altara R, Booz GW, Zouein FA. Kaplan A, et al. Eur J Pharmacol. 2022 Mar 15;919:174787. doi: 10.1016/j.ejphar.2022.174787. Epub 2022 Feb 1. Eur J Pharmacol. 2022. PMID: 35114190 Review.
The therapeutic action of ranolazine was initially attributed to inhibitory effects on fatty acids metabolism. ...A projection of pathologies targeted by ranolazine from cellular level to clinical is provided in this review....
The therapeutic action of ranolazine was initially attributed to inhibitory effects on fatty acids metabolism. ...A projection of pat …
Ranolazine and its Antiarrhythmic Actions.
Polytarchou K, Manolis AS. Polytarchou K, et al. Cardiovasc Hematol Agents Med Chem. 2015;13(1):31-9. doi: 10.2174/187152571301150730113903. Cardiovasc Hematol Agents Med Chem. 2015. PMID: 26245658 Review.
Ranolazine, a newly introduced, FDA-approved antianginal agent, has more recently been shown to have additional beneficial antiarrhythmic actions attributed to its inhibitory effect on both peak and late sodium current. The first clinical evidence of ranolazine's …
Ranolazine, a newly introduced, FDA-approved antianginal agent, has more recently been shown to have additional beneficial antiarrhyt …
Ranolazine for stable angina pectoris.
Salazar CA, Basilio Flores JE, Veramendi Espinoza LE, Mejia Dolores JW, Rey Rodriguez DE, Loza Munárriz C. Salazar CA, et al. Cochrane Database Syst Rev. 2017 Feb 8;2(2):CD011747. doi: 10.1002/14651858.CD011747.pub2. Cochrane Database Syst Rev. 2017. PMID: 28178363 Free PMC article. Review.
However, the effects of ranolazine for people with angina are considered to be modest, with uncertain clinical relevance. ...We found low quality evidence indicating that people with stable angina who received ranolazine showed uncertain effect on the risk of cardio …
However, the effects of ranolazine for people with angina are considered to be modest, with uncertain clinical relevance. ...We found …
Ranolazine and Its Effects on Hemoglobin A1C.
Greiner L, Hurren K, Brenner M. Greiner L, et al. Ann Pharmacother. 2016 May;50(5):410-5. doi: 10.1177/1060028016631757. Epub 2016 Feb 25. Ann Pharmacother. 2016. PMID: 26917816 Review.
In the trial in which a significant difference was not observed, patients assigned to ranolazine received a lower maintenance metformin dose compared with patients not assigned to ranolazine. ...Ranolazine was not associated with an increase in the incidence …
In the trial in which a significant difference was not observed, patients assigned to ranolazine received a lower maintenance metform …
Ranolazine in Cardiac Arrhythmia.
Saad M, Mahmoud A, Elgendy IY, Richard Conti C. Saad M, et al. Clin Cardiol. 2016 Mar;39(3):170-8. doi: 10.1002/clc.22476. Epub 2015 Oct 13. Clin Cardiol. 2016. PMID: 26459200 Free PMC article. Review.
Ranolazine utilization in the management of refractory angina has been established by multiple randomized clinical studies. ...In this review, we will discuss the pharmacological, experimental, and clinical evidence behind ranolazine use in the management of various …
Ranolazine utilization in the management of refractory angina has been established by multiple randomized clinical studies. ...In thi …
1,228 results

Searches related to "ranolazine"